Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813"
- PMID: 28340188
- PMCID: PMC5464435
- DOI: 10.1093/neuonc/now313
Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813"
Comment in
-
Reply to letter on results of NRG Oncology RTOG 9813.Neuro Oncol. 2017 May 1;19(5):739. doi: 10.1093/neuonc/nox008. Neuro Oncol. 2017. PMID: 28340219 Free PMC article. No abstract available.
Comment on
-
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236. Neuro Oncol. 2017. PMID: 27994066 Free PMC article. Clinical Trial.
References
-
- Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407–417. - PubMed
-
- Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–474. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
